0ET Stock Overview A pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Esperion Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Esperion Therapeutics Historical stock prices Current Share Price US$1.89 52 Week High US$3.43 52 Week Low US$1.25 Beta 1.03 1 Month Change -0.66% 3 Month Change 11.64% 1 Year Change -2.35% 3 Year Change -48.85% 5 Year Change -96.24% Change since IPO -90.49%
Recent News & Updates Esperion Therapeutics, Inc. announced that it has received $150 million in funding Dec 19
Esperion Therapeutics, Inc. announced that it has received $42.5 million in funding Dec 18
Esperion Announces New Drug Submissions in Canada for NEXLETOL ® (Bempedoic Acid) and NEXLIZET® (Bempedoic Acid and Ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk Dec 02
Esperion Highlights New Exploratory Data from Clear Outcomes Trial Highlighting Value of NEXLETOL (Bempedoic Acid) in Oral Featured Science Session and Multiple Poster Presentations At Aha Scientific Sessions 2024 Nov 19
Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.37 loss in 3Q 2023) Nov 08
Forecast breakeven date pushed back to 2026 Nov 08 See more updates Esperion Therapeutics, Inc. announced that it has received $150 million in funding Dec 19
Esperion Therapeutics, Inc. announced that it has received $42.5 million in funding Dec 18
Esperion Announces New Drug Submissions in Canada for NEXLETOL ® (Bempedoic Acid) and NEXLIZET® (Bempedoic Acid and Ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk Dec 02
Esperion Highlights New Exploratory Data from Clear Outcomes Trial Highlighting Value of NEXLETOL (Bempedoic Acid) in Oral Featured Science Session and Multiple Poster Presentations At Aha Scientific Sessions 2024 Nov 19
Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.37 loss in 3Q 2023) Nov 08
Forecast breakeven date pushed back to 2026 Nov 08
Esperion Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
Esperion Therapeutics, Inc. Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Sep 04
Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.46 loss in 2Q 2023) Aug 13
Forecast breakeven date pushed back to 2025 Aug 06
Forecast breakeven date pushed back to 2025 Jul 30
Esperion Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024 Jul 25
Forecast breakeven date moved forward to 2024 Jun 30
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination (FDC)), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events May 24
First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.79 loss in 1Q 2023) May 07
Esperion Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 24
Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024 Apr 12 U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Full year 2023 earnings released: US$2.03 loss per share (vs US$3.52 loss in FY 2022) Feb 28
Esperion Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 14
New minor risk - Financial position Jan 22 Esperion Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $85.05 million. Jan 19
U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet Dec 14
New major risk - Shareholder dilution Nov 13
Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023 Nov 12
Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.81 loss in 3Q 2022) Nov 08
No longer forecast to breakeven Nov 08
Esperion Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
New minor risk - Market cap size Oct 05
New major risk - Shareholder dilution Aug 03
Forecast to breakeven in 2024 Aug 02
Esperion Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 15
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet Jun 29
Esperion Therapeutics, Inc. Announces the Results from its Pre-Specified, Primary Prevention Clear Outcomes Subgroup Analysis Jun 27
Forecast breakeven date moved forward to 2024 Jun 16
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment At Endo 2023 Jun 16
Esperion Announces Submission of Supplemental New Drug Applications to U.S. Fda for Nexletol(R) (Bempedoic Acid) Tablet and Nexlizet(R) (Bempedoic Acid and Ezetimibe) Tablet Jun 02
Forecast breakeven date pushed back to 2025 May 22
Forecast breakeven date pushed back to 2025 May 10
First quarter 2023 earnings released: US$0.79 loss per share (vs US$0.93 loss in 1Q 2022) May 09
Full year 2022 earnings released: US$3.52 loss per share (vs US$9.31 loss in FY 2021) Feb 22
Esperion Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Feb 08
Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022 Jan 09
Esperion Therapeutics, Inc. Announces CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology Dec 20
Esperion Therapeutics, Inc. Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint Dec 08
Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer Nov 17
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.81 loss per share (vs US$2.62 loss in 3Q 2021) Nov 02
Esperion Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 18
Esperion Announces Bempedoic Acid NEXLETOL Recommends as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway Aug 27
Second quarter 2022 earnings released: US$1.05 loss per share (vs US$1.67 loss in 2Q 2021) Aug 03
High number of new directors Aug 01
Esperion Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 13
High number of new directors Jul 02
Esperion Appoints J. Martin Carroll to Its Board of Directors Jun 03
High number of new directors Jun 01
First quarter 2022 earnings released: US$0.93 loss per share (vs US$3.50 loss in 1Q 2021) May 04
High number of new directors May 02
Esperion Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 20
Esperion Therapeutics, Inc., Annual General Meeting, May 26, 2022 Apr 15
Esperion Therapeutics, Inc. Announces Appointment of Eric Warren, R.Ph. as Chief Commercial Officer Mar 03
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Esperion Therapeutics, Inc. to Report Q4, 2021 Results on Feb 22, 2022 Feb 09
Forecast breakeven date pushed back to 2024 Jan 22
Forecast breakeven date pushed back to 2024 Jan 14
Esperion Therapeutics, Inc. Provides Earnings Results for the Fourth Quarter of 2021 Jan 12
Third quarter 2021 earnings released: US$2.62 loss per share (vs US$3.07 loss in 3Q 2020) Nov 03
Forecast to breakeven in 2023 Sep 23
Second quarter 2021 earnings released: US$1.67 loss per share (vs US$4.50 profit in 2Q 2020) Aug 04
Robbins Geller Rudman & Dowd LLP and Kahn Swick & Foti, LLC Announces Proposed Settlement in the Esperion Therapeutics Securities Settlement Jun 01
First quarter 2021 earnings released: US$3.50 loss per share (vs US$2.84 loss in 1Q 2020) May 06
Esperion Announces Publication of Rationale and Design of Landmark Clear Cardiovascular Outcomes Trial Evaluating Nexletol (Bempedoic Acid) Tablet in American Heart Journal Apr 29
Esperion Therapeutics, Inc. Announces the Results of Phase 2 Study Evaluating the Combination of Nexletol® (Bempedoic Acid) 180 Mg Tablet, Ezetimibe 10 Mg and Atorvastatin 20 Mg in Patients with Hypercholesterolemia Mar 18
Full year 2020 earnings released: US$5.23 loss per share (vs US$3.59 loss in FY 2019) Feb 25
Revenue misses expectations Feb 25
Esperion Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021 Feb 10
New 90-day low: €20.62 Jan 20
Daiichi Sankyo Europe GmbH and Esperion Therapeutics Announces Swissmedic approval for NILEMDO® Tablet and NUSTENDI Tablet Dec 17
Esperion Therapeutics, Inc. Announces Management Changes Dec 16
Esperion Announces Results of Pooled Data from Four of Phase 3 Trials Presented at the Virtual American Heart Association Scientific Sessions 2020 Nov 14
Third quarter 2020 earnings released: US$3.07 loss per share Nov 05
Revenue misses expectations Nov 05
New 90-day low: €26.12 Oct 29
Esperion Therapeutics, Inc. to Report Q3, 2020 Results on Nov 02, 2020 Oct 20
Esperion Announces Results of Pooled Data from Two of the Company’S Phase 3 Trials Were Presented At the Virtual 88Th Annual Congress of the European Atherosclerosis Society (Eas 2020) Oct 08
New 90-day low - €26.99 Aug 25 Shareholder Returns 0ET DE Pharmaceuticals DE Market 7D -4.3% 4.0% 3.0% 1Y -2.3% -12.8% 13.2%
See full shareholder returns
Return vs Market: 0ET underperformed the German Market which returned 13.2% over the past year.
Price Volatility Is 0ET's price volatile compared to industry and market? 0ET volatility 0ET Average Weekly Movement 24.2% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0ET's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0ET's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
Show more Esperion Therapeutics, Inc. Fundamentals Summary How do Esperion Therapeutics's earnings and revenue compare to its market cap? 0ET fundamental statistics Market cap €406.81m Earnings (TTM ) -€83.33m Revenue (TTM ) €283.72m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0ET income statement (TTM ) Revenue US$295.45m Cost of Revenue US$107.43m Gross Profit US$188.03m Other Expenses US$274.80m Earnings -US$86.77m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.44 Gross Margin 63.64% Net Profit Margin -29.37% Debt/Equity Ratio -71.0%
How did 0ET perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/22 23:59 End of Day Share Price 2025/01/22 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Esperion Therapeutics, Inc. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Zemansky BofA Global Research Thomas Shrader BTIG Kristen Kluska Cantor Fitzgerald & Co.
Show 16 more analysts 
